NVS250417C135000
- 0.25
- 0.000.00%
Novartis AG Newsroom
Novartis Secures Third FDA Approval For Its Kidney Disease Portfolio In One Year
Sector Update: Health Care Stocks Lean Lower Premarket Thursday
Bernstein Reaffirms Their Buy Rating on Novartis AG (NOVN)
Reported Earlier, Novartis Gains FDA Accelerated Approval For Vanrafia, The First Selective ETA Receptor Antagonist For Proteinuria Reduction In IgA Nephropathy
Novartis' Vanrafia Receives Accelerated Approval From US FDA
TG Therapeutics Rises After Trial Setback for High Dose Version of Roche's MS Drug
Novartis (NVS.US) has received approval for a new indication for its "potential blockbuster" drug in China.
On April 2, Novartis (NVS.US) announced that the hydrochloride ipkapan capsule has received approval for a new indication from the National Medical Products Administration (NMPA) of China for the treatment of adult C3 glomerulopathy (C3G) to reduce proteinuria.
Barclays Ups Novartis' Earnings Projections on Strong US Prescriptions
FDA Reviews Kidney Disease Drug From Apellis Pharmaceuticals
Express News | Trump Administration Health Agency Firings Include Staff Overseeing Bird Flu Response
The "Liberation Day" of Trump's tariffs is approaching, and the pharmaceutical Industry may not be among the targets.
According to reports, President Trump of the USA is expected to announce a series of broader tariff measures on local time April 2 (Wednesday), which will not include any specific details on Pharmaceutical tariffs.
Barclays Reaffirms Their Sell Rating on Novartis AG (NOVN)
Alphabet's Isomorphic Labs Unit Raises $600 Million for AI-Based Drug Development
Novartis: Current Chief Ethics, Risk & Compliance Officer Klaus Moosmayer to Step Down
Novartis Appoints Karen Hale, Chief Legal and Compliance Officer
Novartis Obtains US FDA Approval for Prostate Cancer Medication Pluvicto
SA Asks: What Are the Best Large-cap Cardiology Stocks Right Now?
Trump's Medical Tariffs Could Significantly Hurt These European Healthcare Firms
Sector Update: Health Care Stocks Softer Late Afternoon
FDA OKs Novartis Prostate Cancer Treatment, Triples Eligible Patient Pool